Post by : Bianca
Haleem
The FDA has begun a thorough safety assessment of two injectable treatments aimed at safeguarding infants and toddlers from respiratory syncytial virus (RSV), which can lead to significant health challenges and hospitalizations among young children.
Produced by Merck and Sanofi, these long-acting antibody treatments serve not as vaccines but as essential first-line protection for this vulnerable age group. Officials clarified that the review is routine and ensures the continued safety of these medications for wide application.
While RSV typically manifests as cold-like symptoms in healthy individuals, it poses a heightened risk of severe respiratory illness in infants, young children, and the elderly. Although the FDA has approved vaccines for older populations and pregnant women, these antibody treatments are vital for newborns.
Merck’s Enflonsia is given prior to or during a child's initial RSV season, which typically lasts about five months, whereas Sanofi’s Beyfortus has already been administered to over six million children globally. Both corporations report that there are no new safety concerns emerging from ongoing clinical studies or their use in the market.
The CDC previously advised giving antibody shots to infants born just before or during RSV season in cases where the mother was unvaccinated in late pregnancy. Guidance also included some high-risk children aged between 8 to 19 months.
This review is taking place amid enhanced scrutiny of drug and vaccine safety under Health Secretary Robert F. Kennedy Jr., who has undertaken various changes within the CDC, including altering membership on advisory committees and contemplating adjustments to routine newborn vaccinations for hepatitis B.
Officials at the FDA assured that this review does not suggest any specific safety problems. Depending on future data evaluations, product labeling updates may be warranted.
English
